The conflicting results from recent trials highlight a clear gap in the understanding of the effectiveness of combining anti‐angiogenic agent, immunotherapy, with chemotherapy (AICT) for these EGFR mutant NSCLC patients who had disease progression after frontline EGFR‐TKI treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.